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A
lmost 80% of postprandial glucose uptake re-
sides in skeletal muscle (1). Hence, develop-
ment of skeletal muscle insulin resistance is
a hallmark of type 2 diabetes. Muscle is an
ambiguous organ with respect to substrate selection. To
fuel muscle contraction, both glucose and fatty acids can
be oxidized. Glucose first needs to enter the muscle cells
via insulin-mediated GLUT4-dependent transmembrane
transport and then be converted to acetyl-CoA via the
pyruvate dehydrogenase (PDH) complex. Oxidation of
fatty acids, especially long-chain fatty acids, requires mi-
tochondrial entrance via carnitine palmitoyltransferase-1
(CPT-1) prior to subsequent b-oxidation. To explain the
well-known relationship between obesity and type 2 di-
abetes, Sir Philip Randle (2) proposed in 1963 that high
uptake of fatty acids in skeletal muscle resulting from high
free fatty acid levels observed in obesity would result in
high fatty acid oxidation rates (Fig. 1). In turn, this would
reduce glucose oxidation, thereby rendering the muscle
insulin resistant. At the cellular level, high rates of fatty
acid oxidation would result in accumulation of acetyl-CoA
and citrate, thereby inhibiting PDH and glycolysis, ulti-
mately resulting in reduced glucose oxidation. However,
in the previous 2 decades, the concept of the Randle cycle
in skeletal muscle has been challenged. Elegant studies by
Shulman and colleagues (3–5) showed that in type 2 dia-
betes, reduced uptake of glucose due to compromised
GLUT4 translocation, not a reduced glycolytic flux, is the
main culprit in development of skeletal muscle insulin re-
sistance. Moreover, fat accumulation in muscle, and par-
ticularly accumulation of muscle diacylglycerol (DAG),
was suggested to impair GLUT4 translocation in type 2
diabetes (6). Hence, a reduced capacity to oxidize fat
due to mitochondrial dysfunction (7,8) rather than high
rates of fatty acid oxidation as proposed by Randle is
hypothesized to underlie accumulation of triacylglycerol/
DAG in muscle, thus promoting insulin resistance. Al-
though this DAG hypothesis has dominated research on
the cause of myocellular insulin resistance for some 20
years, recent studies challenge the concept that mito-
chondrial dysfunction is the root cause of insulin resis-
tance (rev. in 9).
The article by Keung et al. (10) in this issue of Diabetes
revisits the Randle hypothesis of a reciprocal relationship
between fat and glucose oxidation. Inhibition of mito-
chondrial entry of fatty acids by oxfenicine resulted
in improved glucose tolerance and insulin sensitivity in
high-fat diet–fed mice, while body mass was maintained.
Next, the authors confirmed that oxfenicine was indeed
able to reduce fat oxidation with a concomitant increase in
glucose oxidation facilitated by increased PDH activity.
Interestingly, improvements in muscle glucose handling
were not only observed in the basal state, but also in
insulin-stimulated AKT-phosphorylation, an important
marker of insulin sensitivity. Finally, GLUT4 translocation
was improved.
In a completely independent study, we (11) recently
reported similar findings in mice and humans who were
administered with etomoxir, a pharmaceutical compound
that inhibits CPT-1 and that was in clinical trials for its
antidiabetic effects in the late 1990s. We found that in
humans, 36 h of etomoxir administration increased glu-
cose oxidation and GLUT4 translocation. Longer-term
etomoxir administration in mice improved glucose ho-
meostasis and insulin signaling. Together, these findings
are consistent with the current results of Keung et al. (10).
Furthermore, it was previously shown that mice lacking
malonyl-CoA decarboxylase have elevated malonyl-CoA
levels, which promote the inhibitory effect of malonyl-CoA
on CPT-1, thereby leading to reduced fat oxidation and
improved glucose homeostasis (12). Similarly, Koves et al.
(13) showed that an increase in fatty acid oxidation can
lead to incomplete oxidation of fatty acids, thereby pro-
moting insulin resistance. In follow-up studies, Muoio et al.
(14) recently showed that carnitine acetyltransferase may
function to relieve pressure on the PDH complex when
fatty acid oxidation rates outpace tricarboxylic acid cycle
activity, and that under conditions of carnitine acetyl-
transferase deficiency, high fat oxidation rates may impair
glucose oxidation. Collectively, these studies suggest that
the essentials of the Randle cycle can operate in skeletal
muscle, and that reducing myocellular fat oxidative ca-
pacity to promote insulin sensitivity is a viable approach in
the treatment of type 2 diabetes.
What can we learn from these new studies? First, they
show that our understanding of the mechanism(s) in-
ducing muscle insulin resistance is not yet complete.
Whereas the DAG hypothesis has attracted most attention
the past few years, recent studies challenge the concept
that mitochondrial dysfunction and concomitant elevated
DAG lead to insulin resistance in muscle (11,15,16). Con-
versely, although the Randle cycle has been suggested to
be of minor importance in skeletal muscle for over 3
decades, the novel results of these new studies indicate
that substrate competition between glucose and fatty acids
for oxidation may indeed be relevant in development of
muscle insulin resistance. As is often the case, the truth
may be in the middle, and both theories may prove to play
a role in muscle insulin resistance. Secondly, results of
Keung et al. may provide insight into new targets for di-
abetes treatment. It should be noted, however, that such
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approaches are not without risk. Etomoxir has been
investigated as an antidiabetic drug, but trials were aban-
doned because of severe side effects in nonskeletal muscle
tissues. Furthermore, inhibition of fat oxidation results in
increased circulatory levels of fatty acids, which increases
risk of excessive fat accumulation in ectopic tissues and
may thereby offset improved insulin sensitivity. At the
same time, type 2 diabetes commonly coincides with
reduced fat oxidative capacity (17), and it remains to be
seen if a further reduction in fat oxidation is beneficial in
the diseased state. Therefore, future studies— especially in
humans—are required to identify the specific conditions
when substrate competition is important and when fat
oxidation could be a successful target to force glucose
FIG. 1. Schematic representation of the reciprocal regulation of glucose utilization and fatty acid oxidation. A: The Randle theory proposes that
high fatty acid availability and oxidation negatively affects glucose utilization, thereby contributing to insulin resistance. According to this theory,
high rates of fatty acid oxidation result in the accumulation of acetyl-CoA and citrate, thereby inhibiting PDH and glycolysis at the level of
6-phosphofructo-kinase-1 (PFK), resulting in reduced glucose oxidation and hence reduced glucose uptake. PDH inhibition is caused by acetyl-CoA
and NADH accumulation resulting from fatty acid oxidation, whereas 6-phosphofructo-kinase-1 inhibition results from citrate accumulation in the
cytosol. These effects reroute glucose toward glycogen synthesis via glycogen synthase (GSK). B: Selective reduction of fatty acid oxidation (e.g.,
postprandial state) at the level of CPT-1 could force glucose uptake and oxidation. Keung et al. show that CPT-1 inhibition increases PDH activity,
membrane GLUT4 content, and Akt phosphorylation and improves whole-body glucose tolerance and insulin sensitivity. B-OX, b-oxidation; IRS1,
insulin receptor substrate 1; LCFA, long-chain fatty acid; TCA, tricarboxylic acid.
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oxidation, thereby improving glucose homeostasis. In that
respect, type 2 diabetic patients are characterized by a re-
duced capacity to switch from fat to glucose oxidation
during the transition from the fasted to fed state (18), and
reducing fat oxidation—preferably by limiting fat uptake
into skeletal muscle—in the postprandial state could alle-
viate this metabolic inflexibility. Pending the outcome of
such human studies, substrate competition should be con-
sidered a putative contributor to muscle insulin resistance
and hence a potential target for future intervention.
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